Clinical Trial Update: A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia [Phase 2]

View source ↗

Summary

Phase 2 safety study of oral ELND005 in young adults with Down syndrome without dementia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• ELND005

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Down Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2016-01-29